Announcements - OBI Pharma 台灣浩鼎

2021.Sep.09

Announcement on behalf of Amaran Biotechnology, Inc., a major subsidiary, that the Company’s Board of Directors resolved to revise the Regulations for Issuance and Subscription of 2020 Employee Stock Options

2021.Sep.09

Announcement on behalf of Amaran Biotechnology, Inc., a major subsidiary, that the company’s Board of Directors resolved to change the date for 2021 annual shareholders’ meeting

2021.Sep.07

Supplementary announcement of electronic voting shareholders’ complimentary gift for 2021 annual shareholders’ meeting

2021.Aug.06

The Company’s Board of Directors resolved to issue employee stock options and the subscription rules

2021.Aug.06

New appointment of Audit Committee member

2021.Aug.06

Announcement of the Consolidated Financial Statements for the second quarter of 2021 were authorized for issuance by the Board of Directors

2021.Jul.27

Patent of OBI-858 “Clostridium Botulinum toxin Type A composition, formulation and use thereof” was granted by the Taiwan Intellectual Property Office

2021.Jul.16

Announcement to approve the lifting of non-competition restrictions for directors at the 2021 Annual General Meeting

2021.Jul.16

Announcement on the elected Independent Director at the 2021 Annual General Meeting

2021.Jul.16

Announcement of resolution items from 2021 Annual General Meeting

News

Latest News

Events

Latest events